CRISPR Therapeutics (CRSP +1.26%) could revolutionize the healthcare sector, and that has made CRISPR stock a hot buy. While the company isn't profitable yet, it had its first treatment (for sickle cell disease) approved by regulators in December 2023.
It also has promising treatments in the works for cancer and cardiovascular disease, all utilizing the CRISPR gene editing platform. If you're thinking about investing in CRISPR stock, here's how to do it and what you should know first.
How to buy CRISPR stock
Follow the steps below to buy CRISPR stock.
- Open your brokerage account: Log in to your brokerage account where you handle your investments. If you don't have one yet, take a look at our favorite brokers and trading platforms to find the right one for you.
- Search for CRISPR Therapeutics: Enter the ticker "CRSP" into the search bar to bring up the stock's trading page.
- Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this stock.
- Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you're willing to pay.
- Submit your order: Confirm the details and submit your buy order.
- Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.
NASDAQ: CRSP
Key Data Points
Is CRISPR Therapeutics profitable?
CRISPR Therapeutics isn't profitable. It reported a net loss of $362.7 million in 2024. The company also states in its annual report that it has incurred significant operating losses since its inception and expects to do so for the foreseeable future.
This is normal for biotech companies, which are generally unprofitable for long periods of time while developing treatments. It's one of the main reasons they're a higher-risk investment.
Does CRISPR Therapeutics pay a dividend?
CRISPR Therapeutics doesn't pay a dividend and is unlikely to in the foreseeable future. Biotech stocks rarely pay dividends, since it makes more sense for them to reinvest profits in developing new treatments. People interested in dividend investing don't have many options in this space.
The bottom line
Gene editing is looking like a major innovation for the healthcare industry, and CRISPR Therapeutics is at the forefront. All of its product candidates use the CRISPR gene-editing technique. With one approved product so far and more hopefully on the way, the sky's the limit.
There are a couple of things to keep in mind if you want to invest in CRISPR stock. The risk and reward are both higher with biotech companies than with most market sectors. You also shouldn't expect immediate results with CRISPR Therapeutics, since most of its treatments are still in the early stages. This is a stock for patient investors who are comfortable with volatility.
Related investing topics
FAQs
About the Author
